LEILA ANTONANGELO
Projetos de Pesquisa
Unidades Organizacionais
Departamento de Patologia, Faculdade de Medicina - Docente
Instituto Central, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/03 - Laboratório de Medicina Laboratorial, Hospital das Clínicas, Faculdade de Medicina - Líder
Instituto Central, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/03 - Laboratório de Medicina Laboratorial, Hospital das Clínicas, Faculdade de Medicina - Líder
11 resultados
Resultados de Busca
Agora exibindo 1 - 10 de 11
- Performance of the UroVysion (R) FISH assay for the diagnosis of malignant effusions using two cutoff strategies(2018) ROSOLEN, Debora C. B.; FARIA, Daniel K.; FARIA, Caroline S.; ANTONANGELO, LeilaThe cytological examination of cavity fluids has limited sensitivity in the diagnosis of malignancy. Aneuploidy, which is commonly observed in neoplastic cells, could potentially be used as an ancillary diagnostic tool. To evaluate the detection of aneuploid cells in cavitary effusion samples using the fluorescence in situ hybridization (FISH) assay UroVysion (R) with some adaptations and two different cutoff strategies. Seventy samples of pleural or peritoneal fluid with positive (n = 40), negative (n = 15), or suspicious (n = 15) oncotic cytology were subjected to FISH assay with the multitarget UroVysion (R) kit, which is composed of probes that hybridize to the centromeric region of chromosomes 3, 7, and 17 and to the locus 9p21. FISH performance was evaluated using two different cutoffs: (1) the manufacturer's cutoff (M-FISH) and 2) a proposed cutoff (P-FISH). Using M-FISH, the diagnostic sensitivity was 57.1%, specificity 87.5%, and accuracy 60.0%; with P-FISH, the sensitivity was 87.3%, specificity 71.4%, and accuracy 85.7%. When combined with cytology, the sensitivity, specificity, and accuracy were 88.0%, 83.3%, and 87.8%, respectively. Malignant cells presented a predominance of chromosomal gains. The UroVysion (R) test using the P-FISH cutoff was effective in demonstrating aneuploid cells in all malignant effusions, confirming the diagnosis of malignancy even in cases with suspicious cytology.
conferenceObject Evaluation of a biomarker panel for the diagnosis of cavity effusions(2018) ANTONANGELO, L.; FARIA, C. Silverio; ASCENCIO, M. M. P.; ROSOLEN, D. Cristina Batista; DOI, D.; FARIA, D. KanaanconferenceObject Performance of the UroVysion (R) FISH assay for the diagnosis of malignant effusions using two cutoff strategies(2018) ANTONANGELO, L.; FARIA, D. Kanaan; FARIA, C.; ROSOLEN, D. Cristina BatistaconferenceObject Multiplex Ligation Probe-dependent Amplification (MLPA) as an ancillary method for the diagnosis of malignant pleural effusion(2012) PARRA, E.; ROSOLEN, D.; KULIKOWSKI, L.; DUTRA, R.; CAPELOZZI, V. L.; VARGAS, F.; ACENCIO, M.; ANTONANGELO, L.Objective: A definitive diagnosis provided by the finding of malignant cells in pleural fluid (PF) can be established in around 50 % of patients with pleural malignancy. However, underdiagnosis risk in cytological suspicious cases is high, which makes the cytological diagnosis quite limited. This is an important clinical problem, especially if we consider that some patients, in bad clinical conditions, can not be submitted to a guided thoracoscopic biopsy. Method: Using multiplex ligation probe-dependent amplification (P315-MRC-Holland) we have studied sequence variations of EGFR gene and amplifications/deletions of chromosomal regions frequently associated to tumors (ATG4B, PAHs, PROS, NSD1, and CDGIF genes). Results: Forty-three malignant PF samples from patients with different cancers were evaluated, even in those cases with scarce pellet cells. Four benign pleural effusions were used as control. Gene sequence changes were observed in 13 (30.2 %) cases, while others copy number abnormalities were found in 19 (44.2 %). Conclusion: The findings suggest that MLPA could be considered an alternative tool to detect molecular genetic changes in malignant pleural effusions, since this technique is relatively low expensive and not time consuming. Our next challenge is to find the best combination of probes capable to recognize malignant cells of any origin in fresh samples of PF.conferenceObject USEFULNESS OF MOLECULAR METHODS FOR THE DIAGNOSIS OF MALIGNANT PLEURAL EFFUSIONS(2014) ANTONANGELO, Leila; ROSOLEN, Debora Cristina Batista; CAPELOZZI, Vera Luiza; VARGAS, Francisco Suso; BOTTURA, Giorgio; DUTRA, Ana Rosa N.; MARTINS, Vanessa; LOPES, Annelise C. W.; TEIXEIRA, Lisete RibeiroconferenceObject Detection of aneuploidy by flow cytometry and fluorescence in situ hybridization in the diagnosis of malignant pleural effusion(2014) ROSOLEN, D.; DUTRA, A. R. N.; BOTTURA, G.; SILVA, V. M. da; CAPELOZZI, V. L.; VARGAS, F. S.; ANTONANGELO, L.conferenceObject Efficacy of the UroVysion kit for the diagnosis of malignant pleural effusion(2016) ANTONANGELO, L.; DUTRA, A. R. N.; NETO, E. Terreri; MORENA, L. C.; CAPELOZZI, V. L.; TERRA, R. M.; ROSOLEN, D. C. B.conferenceObject Frequency of genetic abnormalities in malignant pleural effusion(2016) ANTONANGELO, L.; DUTRA, A. R. N.; NETO, E. Terreri; MOREIRA, L. C.; CAPELOZZI, V. L.; TERRA, R. M.; ROSOLEN, D. C. B.- Transient abnormal myelopoiesis with pericardial effusion in Down syndrome: Case report(2019) FALASCO, Bianca Francisco; DURANTE, Brenda; FARIA, Daniel Kanaan; FARIA, Caroline Silveri; ROSOLEN, Debora Cristina Batista; ANTONANGELO, LeilaPericardial effusion associated with transient abnormal myelopoiesis in Down's syndrome neonates needs to be diagnosed in a timely manner, and the comorbidities must be treated to prevent mortality. To our knowledge, the occurrence of basophilic/eosinophilic pericardial effusion without an increase of these cells in the peripheral blood and with no evidence of associated hypothyroidism is rare.
conferenceObject Adaptation of UroVysion kit for the diagnosis of malignant pleural effusion(2014) ANTONANGELO, L.; ROSOLEN, D. C. B.; DUTRA, A. R. N.; BOTTURA, G.; SILVA, V. M.; CAPELOZZI, V. L.